Performance of a Whole-Blood Interferon-Gamma Release Assay with Mycobacterium RD1-Specific Antigens among HIV-Infected Persons.
OBJECTIVE
To evaluate the usefulness of one of IGRAs, QuantiFERON-TB Gold (QFT-G), in human immunodeficiency virus- (HIV-) infected patients with various CD4(+) T cell counts.


METHODS
The QFT-G assay was performed using QFT-G kits among 107 HIV-infected patients including 9 cases with active tuberculosis (TB).


RESULTS
In HIV-infected patients with CD4(+) > 50/microL, QFT-G positive rate for active TB patients was 5/6 (sensitivity = 83%), and that for those without active disease was 1/69 (specificity = 99%). The frequency of indeterminate QFT-G test was significantly higher in those with CD4(+) less than 50/microL (P < .0001). At the same time there was a proportional relationship between CD4(+) and interferon-gamma response to mitogen (positive control) in QFT-G test (P = .0001). Conclusions. Our data suggested that QFT-G had high sensitivity and specificity in HIV-infected populations with CD4(+) greater than 50/microL. However, QFT-G did not perform well in HIV-positive patients with CD4(+) less than 50/microL.
Fujita
Akira
A
Department of Pulmonary Medicine, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-shi, Tokyo 183-8524, Japan. akira_fujita@tmhp.jp
Ajisawa
Atsushi
A
Harada
Nobuyuki
N
Higuchi
Kazue
K
Mori
Toru
T
D000328:Adult; D000368:Aged; D000942:Antigens, Bacterial / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D006801:Humans; D007159:Immunologic Tests / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000097:blood*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000276:immunology; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D014374:Tuberculin Test; D014376:Tuberculosis / Q000097:blood / Q000150:complications* / Q000175:diagnosis*; D055815:Young Adult
D000942:Antigens, Bacterial; D011933:Reagent Kits, Diagnostic; D007371:Interferon-gamma
MMWR Recomm Rep. 1998 Oct 30;47(RR-20):1-58
9809743
MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51
10881762
Kekkaku. 2004 Dec;79(12):725-35
15782618
Clin Infect Dis. 1993 Dec;17(6):968-75
8110954
MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4
19357635
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55
16357824
Kekkaku. 1960 Aug;35:563-6
13765102
Kekkaku. 2006 May;81(5):393-7
16886264
Am J Respir Crit Care Med. 2007 Apr 1;175(7):737-42
17218620
Kekkaku. 2007 Aug;82(8):635-40
17874571
J Infect Chemother. 2009 Jun;15(3):143-55
19554399
Lancet. 2000 Sep 23;356(9235):1099-104
11009160
Lancet Infect Dis. 2007 Jun;7(6):428-38
17521596
Jpn J Infect Dis. 2005 Dec;58(6):S19-21
16377859
BMC Infect Dis. 2009 Feb 10;9:15
19208218
Clin Infect Dis. 2009 Apr 1;48(7):954-62
19245343
Respir Res. 2006 Apr 01;7:56
16579856
J Infect. 2008 May;56(5):348-53
18395264
Infect Immun. 1996 Jan;64(1):16-22
8557334
Expert Rev Mol Diagn. 2009 Mar;9(2):165-77
19298140